Wednesday, 21 Nov 2018

Unknown content type

RheumNow Week in Review – The Heart Attack Report (11.2.18)

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Ixekizumab COAST-V Trial Wins in Axial Spondyloarthritis

Lancet has published the results of a study showing that ixekizumab (an IL-17A inhibitor) yielded significant clinical benefit and radiographic protection when given to NSAID treated patients with radiographic axial spondyloarthritis (AxSpA).

Update on Checkpoint Inhibitor Safety

“Autoimmunity is the Achilles heel of onco-immunotherapy” per Dr. Leonard Calabrese, which leaves a dilemma for rheumatologists. Onco-immunotherapy induces immune dysregulation to allow patients to develop an immune response to their cancer cells. An unfortunate side effect for patients taking onco-immunotherapy is often autoimmune-like diseases referred to as immune adverse reactions (irAEs). Studies in France and the United States have shown that irAEs can be a good prognostic sign, suggesting these therapies are working. Rheumatology is faced with new problems as onco-immunotherapies may induce new chronic diseases in multiple different forms secondary to the treatment.

Doubling Down on IL-17 In Psoriatic Arthritis

The monoclonal antibody bimekizumab, which neutralizes both interleukin (IL)-17A and 17F, was effective for both musculoskeletal and skin outcomes in psoriatic arthritis (PsA) in a phase IIb study.

A New Era? JAK inhibitors in the Management of RA

ACR 2018 has come and gone. It was a conference filled with a number of highlights. One thing from this conference which really stood out was the continued plethora of data on JAK inhibitors. First in RA, and now in psoriatic arthritis and psoriasis.

Spotlight on Interstitial Lung Disease at ACR 2018

Here are a few important advances in our understanding of interstitial lung disease (ILD) from the ACR 2018 meeting last week.

Imaging Reveals Anatomical Focus of Inflammation in PMR

Two studies presented at ACR18 have used imaging to examine one of the key unanswered questions in polymyalgia rheumatica - what structures are the focus of inflammation in the disease – and demonstrated that peritendineal involvement is ubiquitous in and distinctive of PMR.

Anti-phospholipid Antibodies and Myocardial Infarction.

The Annals of Internal Medicine features a communique from the Karolinska Institutet in Sweden demonstrating that elevated levels of antiphospholipid antibodies may be found in patients with myocardial infarction without any autoimmune co-morbidity, published in Annals of Internal Medicine reports.

'These Results Are Astonishing': What We Heard at ACR 2018

"If radiation was a drug that could improve survival in the metastatic setting like that it would be millions and millions of dollars." -- James B. Yu, of Yale Cancer Center, discussing aggressive use of stereotactic body radiation therapy in oligometastatic cancer.

*******************************************************

Treat-to-Target Strategy Cuts Mortality in Gout Patients

More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.

RheumNow ACR Week in Review: ACR Wrap-Up (10.26.18)

This past week in Chicago gave us a plethora of new and eye-opening research, people, KOLs, exhibits, sessions, guidelines, posters and a never-ending supply of coffee served in small paper cups.  ACR 2018 highlights for me included:

Update on Myositis

The ACR/ARHP 2018 national meeting in Chicago presented us with opportunities to learn more about inflammatory myositis. A particularly interesting lecture was HOT topics in myositis. There were a few abstracts on MDA-5 related disease and a few on new or repurposed medications for dermatomyositis which will be covered here.